BAR502, is a dual FXR and GPBAR1 agonist32–34, that is currently advanced to clinical stage, that was shown effective in reducing steatosis and fibrosis in rodents model of NAFLD and NASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.